Australia markets closed

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
22.39+0.05 (+0.22%)
At close: 04:00PM EDT
22.38 -0.01 (-0.04%)
After hours: 07:21PM EDT

Fulgent Genetics, Inc.

4399 Santa Anita Avenue
El Monte, CA 91731
United States
626 350 0537
https://www.fulgentgenetics.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees1,184

Key executives

NameTitlePayExercisedYear born
Mr. Ming HsiehChairman & CEO2.31MN/A1956
Mr. Jian XieCOO & President868.74kN/A1966
Mr. Paul KimChief Financial Officer879.61kN/A1967
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.Chief Scientific Officer & Laboratory Director720.7kN/A1967
Ms. Natalie PrescottGeneral Counsel & Chief Privacy OfficerN/AN/AN/A
Ms. Doreen NgVP of Operations & Compliance and GM of Houston OfficeN/AN/AN/A
Mr. Jakub SramVice President of Business Development & SalesN/AN/AN/A
Ms. Ellen TsuiVice President of Human ResourcesN/AN/AN/A
Mr. Brandon PerthuisChief Commercial OfficerN/AN/AN/A
Dr. Lawrence M. Weiss M.D.Chief Medical OfficerN/AN/A1957
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Corporate governance

Fulgent Genetics, Inc.’s ISS governance QualityScore as of 1 July 2024 is 6. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.